(2013) Management of Symptomatic Vulvovaginal Atrophy: 2013 Position Statement of The North American Menopause Society. Menopause, 20, 888-902; quiz 3-4.

has been cited by the following article:

• TITLE: Evaluation of the CO2 Laser Therapy on Vulvo-Vaginal Atrophy (VVA) in Oncological Patients: Preliminary Results

  AUTHORS: Isabella Pagano, Stefania Gieri, Francesca Nocera, Giuseppe Scibilia, Filippo Fraggetta, Antonio Galia, Mauro Gioè, Basilio Pecorino, Paolo Scollo

  KEYWORDS: Laser CO2, Vaginal Atrophy, Urinary Incontinence, Menopause

  JOURNAL NAME: Journal of Cancer Therapy, Vol.8 No.5, May 26, 2017

  ABSTRACT: Objective: To evaluate the impact of fractionated CO2 laser therapy on vaginal atrophy and mild/moderate stress urinary incontinence (SUI) symptoms in patients with physiological or surgically-induced menopause. Materials and Methods: Post-menopausal patients (n = 33) presenting vaginal atrophy and/or SUI, underwent three vaginal CO2 laser treatment sessions, performed at 1-month intervals. Vaginal symptoms were evaluated using the Vaginal Health Index Score (VHI-S), Visual Analogue Scales (VAS) for dyspareunia and global patient satisfaction. The impact of urinary incontinence on patient quality of life was evaluated using the International Consultation on Incontinence Questionnaire (ICIQ). Symptoms were evaluated before treatment and at every subsequent treatment session, as well as 3 months following the last treatment session. RESULTS: The three-session treatment series led to a significant improvement in both subjective symptoms (dryness, burning, dyspareunia) and clinical signs (VHI-S) (P Conclusions: Fractionated CO2 laser therapy is a safe, effective and easy-to-perform treatment modality for menopause-related vaginal atrophy and SUI.